WASHINGTON, D.C. (WDNews) – The U.S. Food and Drug Administration announced Thursday that the national shortage of sodium chloride 0.9% injection products—commonly known as IV saline—has officially ended.
FDA Commissioner Dr. Marty Makary called the resolution a “significant milestone for public health” and praised federal and private-sector efforts to expand manufacturing and stabilize supply chains.
The shortage, which affected hospitals and healthcare providers across the country, led the FDA to take emergency steps such as facilitating temporary imports and expediting regulatory reviews to boost production.
“These products will now be removed from the FDA’s Drug Shortage Database,” Makary said, urging health systems to use FDA-approved saline when available.
While the saline shortage has been resolved, the FDA noted that other IV fluids remain in short supply. Officials said they continue working closely with manufacturers to monitor availability and prevent future disruptions.
The announcement aligns with the Trump administration’s broader push to strengthen the domestic drug and medical supply chain, according to Makary.
